舒更葡糖逆转神经肌肉阻滞的安全性:基于WHO药物警戒数据库的上市后研究
本研究基于VigiBase数据库2010至2019年数据,对2032例舒更葡糖相关不良事件进行不成比例分析。常见反应包括神经肌肉阻滞复发、喉痉挛、支气管痉挛和心动过缓;心脏疾病患者及65岁以上者致命病例更常见,0-17岁组ADRs发生率更高。
要点
- 舒更葡糖相关常见ADRs为神经肌肉阻滞复发、喉痉挛、支气管痉挛和心动过缓。
- 心脏疾病患者及65岁以上者致命病例更常见,用药后应监测心电图和血流动力学。
- 0-17岁组ADRs发生率高于其他年龄组,常见ADRs多在给药后1天内发生。
核心结论
- 麻醉医师应仔细监测麻醉恢复期以纠正舒更葡糖所致ADRs,并建议在整个麻醉过程中监测神经肌肉功能。
- 心血管疾病患者应谨慎使用舒更葡糖,用药后应监测心电图和血流动力学变化。
研究设计与样本
- 基于VigiBase数据库2010至2019年舒更葡糖相关不良事件的上市后药物警戒研究。
- 按MedDRA进行组查询分类,采用信息成分(IC)进行不成比例分析,IC阳性视为显著。
主要发现
- 常见反应为神经肌肉阻滞复发(n=54,IC 6.74,IC025 6.33)、喉痉挛(n=53,IC 6.05,IC025 5.64)、支气管痉挛(n=119,IC 5.63,IC025 5.36)和心动过缓(n=169,IC 5.13,IC025 4.90)。
- 致命病例更常见于心脏疾病患者,尤其是65岁以上者。
- 不同年龄组常见ADRs不同(P < .01),0-17岁组ADRs高于其他年龄组。
- 常见ADRs发生时间通常 within 1 day,68.9%在舒更葡糖给药后半小时内发生。
临床怎么用
- 麻醉恢复期应密切监测舒更葡糖相关ADRs,并在整个麻醉过程中监测神经肌肉功能。
- 心血管疾病患者使用舒更葡糖应谨慎,用药后监测心电图和血流动力学变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Residual neuromuscular blockade is a common complication after general anaesthesia. Sugammadex can reverse the action of aminosteroid neuromuscular blockers. This study aimed to explore sugammadex safety issues in the real world and determine the spectrum of adverse reactions. METHODS: All sugammadex-related adverse events reported in VigiBase between 2010 and 2019 were classified by group queries according to the Medical Dictionary for Regulatory Activities. A disproportionality analysis of data was performed using the information component (IC); positive IC values were deemed significant. RESULTS: Overall, 16 219 410 adverse events were reported and 2032 were associated with sugammadex. The frequent reactions were recurrence of neuromuscular blockade (n = 54, IC 6.74, IC025 6.33), laryngospasm (n = 53, IC 6.05, IC025 5.64), bronchospasm (n = 119, IC 5.63, IC025 5.36) and bradycardia (n = 169, IC 5.13, IC025 4.90). Fatal cases were more likely among patients with cardiac disorders, especially those over 65 years. In addition, the common adverse drug reactions (ADRs) differed between different age groups (P < .01). ADRs were higher in the 0-17 years age group than in other age groups. The onset time of common ADRs was typically within 1 day and 68.9% occurred within half an hour after sugammadex administration. CONCLUSIONS: Anaesthesiologists should carefully monitor the anaesthesia recovery period to correct the ADRs caused by sugammadex and recommend monitoring neuromuscular function throughout the anaesthesia process. Sugammadex should be used carefully in patients with cardiovascular diseases, and electrocardiography and hemodynamic changes should be monitored after medication.
引用
- Lyu Q, Ye P, Zhang H, et al. Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2022. PMID: 35607986. doi:10.1111/bcp.15417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。